A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

Clinical trial NCT01035502 · COMPLETED

Trial details

NCT number: NCT01035502
Sponsor: Clavis Pharma
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2009-12-01
Primary completion: 2013-05-01
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.